Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 513-526 , August 2010

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes

  • Richard J. Riese, MD, PhD

      Affiliations

    • Pfizer Global Research and Development, New London, CT, USA
    • ,
  • Sriram Krishnaswami, PhD

      Affiliations

    • Pfizer Global Research and Development, New London, CT, USA
    • ,
  • Joel Kremer, MD

      Affiliations

    • Albany Medical College, Albany, NY, USA
    • Corresponding Author InformationCorresponding author. The Center for Rheumatology, 1367 Washington Ave., Albany, NY 12206, USA. Tel.: +1 518 489 4496; Fax: +1 518 533 1380.

References 

  1. Egwuagu CE. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine. 2009;47:149–156
  2. Leonard WJ, O’Shea JJ. Jaks and STATs: biological implications. Annual Review of Immunology. 1998;16:293–322
  3. O’Sullivan LA, Liongue C, Lewis RS, et al. Cytokine receptor signaling through the Jak–Stat–Socs pathway in disease. Molecular Immunology. 2007;44:2497–2506
  4. Kawamura M, McVicar DW, Johnston JA, et al. Molecular cloning of L-JAK, a Janus family protein–tyrosine kinase expressed in natural killer cells and activated leukocytes. Proceedings of The National Academy of Sciences of the United States of America. 1994;91:6374–6378
  5. Nosaka T, van Deursen JM, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science. 1995;270:800–802[published erratum appears in Science 1996; 271: 17]
  6. Thomis DC, Gurniak CB, Tivol E, et al. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science. 1995;270:794–797
  7. Park SY, Saijo K, Takahashi T, et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity. 1995;3:771–782
  8. Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature. 1995;377:65–68
  9. Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995;270:797–800
  10. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302:875–878
  11. West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Current Opinion in Investigational Drugs. 2009;10:491–504
  12. Li X, Jesson M, Lee J et al. Characterization of a potent inhibitor of JAK kinases, CP-690,550, and inhibition of specific JAK/STAT pathways at efficacious exposures in a rodent model of arthritis. Abstract presented at the 15th International Inflammation Research Association Conference, Chantilly, Virginia, September 21-24, 2008.
  13. Milici AJ, Kudlacz EM, Audoly L, et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Research & Therapy. 2008;10:R14
  14. Paniagua R, Si MS, Flores MG, et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation. 2005;80:1283–1292
  15. Borie DC, Changelian PS, Larson MJ, et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation. 2005;79:791–801
  16. Rousvoal G, Si MS, Lau M, et al. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transplant International. 2006;19:1014–1021
  17. Kudlacz E, Perry B, Sawyer P, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. American Journal of Transplantation. 2004;4:51–57
  18. Rousvoal G, Zhang S, Berry GJ, et al. JAK3 inhibition with CP-690,550 prevents obliterative bronchiolitis in a rat tracheal transplant model. Transplantation. 2004;78:46;O120 (abstract)
  19. Kudlacz E, Conklyn M, Andresen C, et al. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. European Journal of Pharmacology. 2008;582:154–161
  20. Lawendy N, Krishnaswami S, Wang R, et al. Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers. Journal of Clinical Pharmacology. 2009;49:423–429
  21. Krishnaswami S, Kudlacz E, Yocum S, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of CP-690,550, a Janus kinase inhibitor. The AAPS Journal. 2009;11:36;(abstract)
  22. Hutmacher MM, Krishnaswami S, Kowalski KG. Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. Journal of Pharmacokinetics and Pharmacodynamics. 2008;35:139–157
  23. Prakash C, Lin J, Chan G, Boy M. Metabolism, pharmacokinetics and excretion of a Janus kinase-3 inhibitor, CP-690,550, in healthy male volunteers. The AAPS Journal. 2008;10:2492;(abstract)
  24. Chow V, Krishnaswami S, Chan G. Pharmacokinetics of CP-690,550, a Janus kinase inhibitor, in subjects with impaired renal function and end-stage renal disease. Clinical Pharmacology And Therapeutics. 2009;85:PII-86 (abstract)
  25. Chow V, Ni G, LaBadie R, Chan G. Open label study to estimate the effect of fluconazole on the pharmacokinetics of a JAK3 antagonist (CP-690,550) in healthy adult subjects. Clinical Pharmacology And Therapeutics. 2008;83:PI-93 (abstract)
  26. Chow V, Wilkinson B, LaBadie R, et al. Open label study of the pharmacokinetics of a JAK3 antagonist (CP-690,550) and single doses of oral methotrexate in rheumatoid arthritis subjects. Clinical Pharmacology And Therapeutics. 2008;83:PI-92 (abstract)
  27. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dose levels of CP-690,550 versus placebo. Arthritis and Rheumatism. 2009;60:1895–1905
  28. Prevoo ML, van ’t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism. 1995;38:44–48
  29. van Gestel AM, Prevoo ML, ’t Hof MA, et al. Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteria. Arthritis and Rheumatism. 1996;39:34–40
  30. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Annals of The Rheumatic Diseases. 2010;69:413–416
  31. Kremer JM, Cohen S, Wilkinson B, et al. Safety and efficacy after 24 week (WK) dosing of the oral JAK inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) in patients (PTS) with active rheumatoid arthritis (RA). Arthritis and Rheumatism. 2009;60(S719):1925;(abstract)
  32. Kremer JM, Cohen S, Wilkinson B et al. The oral Jak inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) is efficacious, safe and well tolerated in patients with active rheumatoid arthritis (RA) with an inadequate response to methotrexate alone. Abstract presented at the American College of Rheumatology, San Francisco, California, October 24-29, 2008.
  33. Wallenstein G, Cohen S, Cutolo M, et al. Effects of the oral jak inhibitor CP-690,550 (CP) on pain, physical functioning (PF), fatigue, and health-related quality of life (HRQoL) in patients (pts) with active rheumatoid arthritis (RA). Arthritis and Rheumatism. 2009;60(S154):418;(abstract)
  34. Fleischmann RM, Genovese MC, Gruben D, et al. Safety and efficacy after 24 week (wk) dosing of the oral JAK inhibitor CP-690,550 (CP) as monotherapy in patients (pts) with active rheumatoid arthritis (RA). Arthritis and Rheumatism. 2009;60(S718):1924;(abstract)
  35. Kanik K, Fleischmann RM, Cutolo M, et al. Phase 2B dose ranging monotherapy study of the oral JAK inhibitor CP-690,550 (CP) or adalimumab (ADA) vs placebo (PBO) in patients (pts) with active rheumatoid arthritis (RA) with an inadequate response to DMARDs. Annals of The Rheumatic Diseases. 2009;68:123;OP-0159 (abstract)
  36. Tanaka Y, Suzuki M, Nakamura H et al. The oral JAK inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) is efficacious, safe and well tolerated in Japanese patients (pts) with active rheumatoid arthritis (RA) with an inadequate response to MTX alone. Abstract presented at the The European League Against Rheumatism, Copenhagen, Denmark, June 10-13, 2009.
  37. Connell C, Silverfield J, Forejtova S, et al. Long-term follow-up of patients (pts) with moderate to severe rheumatoid arthritis (RA) treated with the oral JAK inhibitor CP-690,550 (CP). Annals of The Rheumatic Diseases. 2009;68:131;OP-0181 (abstract)
  38. Boy M, Wang C, Wilkinson B, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of cp-690,550 in patients with psoriasis. The Journal of Investigative Dermatology. 2009;129:2299–2302
  39. Busque S, Leventhal J, Brennan D, et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP690,550: a pilot study in de novo kidney allograft recipients. American Journal of Transplantation. 2009;9:1936–1945

☆ Disclosures: Richard Riese and Sriram Krishnaswami are employees of Pfizer. The CP-690,550 studies reviewed in this article were sponsored by Pfizer Inc.

PII: S1521-6942(10)00027-6

doi: 10.1016/j.berh.2010.02.003

Best Practice & Research Clinical Rheumatology
Volume 24, Issue 4 , Pages 513-526 , August 2010

Article Tools

* Image Usage & Resolution